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Abstract
 
T cell receptors recognize small changes in peptide ligands leading to different T cell responses.
Here, we analyzed a panel of HLA-A2–Tax11-19 reactive T cell clones to examine how small
allelic variations of MHC molecules could alter the functional outcome of antigen recognition.
Similar to the effects induced by antigenic altered peptide ligands, weak or partial agonistic T
cell functions were identified in individual T cell clones with the recognition of MHC-altered
peptide ligands (MAPLs). Interestingly, one subtype of HLA-A2 molecules induced an unusual
type of partial agonistic function; proliferation without cytotoxicity. Modeling of crystallo-
graphic data indicated that polymorphic amino acids in the HLA-A2 peptide binding groove,
especially the D-pocket, were responsible for this partial agonism. Reciprocal mutations of the
Tax peptide side chain engaging the D-pocket indeed restored the agonist functions of the
MHC–peptide complex. Whereas early intracellular signaling events were not efficiently in-
duced by these MAPLs, phosphorylated c-Jun slowly accumulated with sustained long-term
expression. These data indicate that MAPLs can induce atypical partial agonistic T cell function
through structural and biochemical mechanisms similar to altered peptide ligands.
Key words: cytotoxic T lymphocyte • HLA-A2 subtypes • cytotoxicity • proliferation • 
MHC-altered peptide ligand
 
Introduction
 
The TCR does not act in a binary fashion as either an “on”
(activated) or “off” (unresponsive) switch, but instead can
be differently engaged by the MHC–peptide complex to
elicit a variety of functional outcomes (1). Depending on
the capacity to elicit T cell responses, TCR ligands can be
classified as an agonist, partial agonist, or antagonist. The
agonistic ligands include full agonists, which are highly
immunogenic and elicit the full array of T cell effector
functions, and weak agonists, which elicit the full array of
T cell effector functions but at decreased levels and only
when significantly greater amounts of peptide antigen are
used. Partial agonists are defined to selectively induce some
effector functions while failing to induce others. Antagonist
peptides, when presented in combination with native,
immunogenic peptide, can inhibit effector function.
The molecular basis of TCR recognition of MHC–pep-
tide complexes has been elucidated by the crystallo-
graphic analysis of a number of MHC–peptide complexes
and more recently trimolecular complexes, including the
TCR–Tax11-19–HLA-A2 (A
 
*
 
0201) complex. H-bonds
between conserved MHC side chains and polar backbone
atoms of the peptide termini provide a general peptide
binding capacity, whereas more limited peptide sequence
selectivity is introduced by the binding of a few peptide
“anchor” side chains in pockets formed by polymorphic
MHC side chains (2–5). Although the terminal anchor side
chains of antigenic peptides are bound similarly in the
MHC structure, the main chains and side chain conforma-
tions can be very different in the center of the binding site.
The crystal structure of TCR–Tax11-19–HLA-A2 trimo-
lecular complex shows that the TCR is oriented diagonally
across the MHC–peptide complex surface. This binding
mode allows the flat TCR surface to interact with the pep-
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tide by fitting between the highest points of the MHC he-
lices (6). The only exception is a deep pocket located at the
center of TCR, which is shaped by the CDR3 loops of
both TCR 
 
 
 
 and 
 
 
 
 chains. This pocket is occupied by Y5
of the Tax peptide (6). The total contact surface of the
MHC–peptide complex with TCR is relatively small, ap-
proximately a third of which is contributed by peptide
(
 
 
 
326 Å
 
2
 
 of 998 Å
 
2
 
). Interestingly, structural comparison
among the A6-TCR and four different peptides including
agonist, partial agonists, and antagonists–HLA-A2 com-
plexes, failed to show a correlation between the types of
minor structural adjustments at the interface and the func-
tional outcomes (7).
The kinetic analyses investigating TCR binding to
MHC–peptide complexes greatly contributed to our un-
derstanding of the underlying mechanism for the discrimi-
nation of ligands by the TCR. It has been generally ob-
served that less potent ligands have a lower affinity and a
faster dissociation rate (8, 9). The kinetic proofreading
model based on these analyses predicts that partial or antag-
onist ligands cannot engage the TCR for the time required
to activate all the downstream signaling pathways due to
low affinity and fast dissociation (10). It was also demon-
strated that the shorter off time of TCR engagement with
the MHC–altered peptide complex allows for the recruit-
ment of different signaling complexes associated with im-
mune receptor tyrosine-based activation motifs of the
TCR 
 
 
 
 chain (11). However, there are some exceptions to
this model (12, 13), and it is currently not possible to mea-
sure TCR affinities and dissociation rates under physiologi-
cal conditions (the interaction between membrane bound
forms of TCR and MHC–peptide molecule).
Although altered TCR ligands represent a complex be-
tween the TCR and MHC–peptide complexes, partial ag-
onist and antagonist of TCR-associated functions have
been examined predominantly with alterations of the pep-
tide antigen. The structural data of TCR recognition of
Tax11-19 presented by HLA-A
 
*
 
0201 allowed us to analyze
how subtle changes in MHC structure could potentially al-
ter the peptide ligand, resulting in partial T cell agonist
function of the MHC–peptide complex.
Here, we demonstrate that amino acid changes in HLA-
A2 subtypes induce major functional changes of T cell rec-
ognition of peptide antigen, analogous to effects seen with
amino acid changes in peptide itself. Interestingly, one sub-
type of HLA-A2 molecule elicited proliferative activity
without cytotoxicity from T cell clones when presenting
peptide. This functional phenotype does not follow the hi-
erarchy of T cell responses in relation to the previously
well established activation thresholds (14, 15). From the
analysis of structural interaction between TCR and MHC–
peptide complex, this specific partial agonistic T cell func-
tion was closely related with an amino acid change of
MHC molecule located in the peptide-binding groove.
Thus, it appears that changes in the MHC peptide-binding
groove induced alterations on the bound peptide that could
be recognized by the TCR. Reciprocal alterations of the
Tax11-19 peptide side chain predicted to engage the MHC
 
pocket allowed for restoration of the agonist functional ac-
tivity of the MHC–peptide complex. Our signaling data
suggest that this partial agonistic function comes from inef-
ficient proximal activation processes, which are directly re-
lated with cytotoxicity, but cumulative intermediate signals
lead to proliferation.
 
Materials and Methods
 
Peptides.
 
Tax11-19 peptide (LLFGYPVYV) was synthesized
(Bio-Synthesis) and was 
 
 
 
93% pure as determined by HPLC.
Tax11-19 peptide analogues with a single amino acid substitution
at position 3 were synthesized by Chiron Mimotopes at a 1-mg
scale on pins and provided by Dr. Wucherpfennig (Dana-Farber
Cancer Institute, Boston, MA).
 
Cell Lines.
 
EBV-transformed B cell lines expressing HLA-
A
 
*
 
0201 (KS.B) or A
 
*
 
0205 (DAH) were generated by incubation
of PBMCs in the presence of supernatant from EBV-producing
cell line B95.8 and 1 
 
 
 
g/ml cyclosporin A. EBV-transformed B
cell lines expressing HLA-A
 
*
 
0203 (FUN) or A
 
*
 
0206 (CLA) and
mouse B cell lymphoma P815 transfected with HLA-A
 
*
 
0202
were characterized previously and provided by Dr. Sette (Epim-
mune, San Diego, CA; reference 16). These lymphoblastoid cell
lines (LCLs)
 
*
 
 were cultured in RPMI 1640 supplemented with
10% heat-inactivated fetal calf serum and used as APCs or target
cells.
 
Human CD8
 
 
 
 T Cell Clones Reactive to Tax11-19.
 
A panel of
Tax11-19–reactive T cell clones were generated by the single cell
sorting and expansion of HLA-A
 
*
 
0201–Tax11-19 tetramer bind-
ing CD8
 
 
 
 T cells obtained from an HLA-A
 
*
 
0201 expressing pa-
tient with typical HTLV-I associated myelopathy as described pre-
viously (17). KS2E11.7 T cell clone was produced from PBMCs
of another HTLV-1–infected patient by repeated antigenic stimu-
lation and limiting dilution method as described previously (18).
The different clonal origin of these T cell clones has been defined
by their different TCR 
 
 
 
/
 
 
 
 chain usages and CDR3 region se-
quences (17, 19). T cell clones were expanded by the stimulation
with PHA in the presence of allogeneic irradiated (5,000 rad) PBMCs
in complete medium (RPMI 1640 supplemented with 10% hu-
man serum [Omega], 4 mM glutamine, 100 U/ml penicillin, 100
 
 
 
g/ml streptomycin, and 10 mM Hepes; reference 17), and were
used in functional assays 9–14 d after PHA stimulation.
 
Cytotoxicity Assay.
 
Cytotoxicity was measured by a standard
4-h 
 
51
 
Cr release assay as described previously (17). Delayed cyto-
toxicity was examined by counting of viable target cells after co-
culture. Target cells were first labeled with carboxyl fluorescein
succinimidyl ester (CFSE; Molecular Probes) in PBS at a final
concentration of 1 
 
 
 
M for 5 min and pulsed with 10 
 
 
 
M of pep-
tides. Peptide-pulsed target cells were cocultured with effector T
cells for the indicated times. Apoptotic or dead cells were stained
with annexin V–PE apoptosis detection kit I (BD Biosciences)
according to the manufacturer’s instructions. The number of via-
ble target cells was analyzed on a flow cytometer (FACScan™;
Becton Dickinson) in CFSE-labeled target cells with the exclu-
sion of annexin V and 7-AAD–stained cells by acquisition of cells
for a constant time. Each sample was counted three times and the
average number of cells was calculated.
 
*
 
Abbreviations used in this paper:
 
 APL, altered peptide ligand; CFSE, car-
boxyl fluorescein succinimidyl ester; LAT, linker for activation of T cells;
LCL, lymphoblastoid cell line; MAPK, mitogen-activated protein kinases;
MAPL, MHC-altered peptide ligand. T
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Proliferation Assay.
 
Proliferation was assessed by [
 
3
 
H]thymi-
dine incorporation assay. For the preparation of APCs, LCLs
were irradiated with 5,000 rad, pulsed with the indicated concen-
trations of peptide for 2 h at 37
 
 
 
C, and washed twice in complete
medium to remove free peptide. 2 
 
 
 
 10
 
4 
 
APCs and 10
 
5 
 
CD8
 
 
 
 T
cell clones were added to each well of 96-well round-bottom
plates in a final volume of 200 
 
 
 
l, and were cultured for 72 h, in-
cluding pulse with 1 
 
 
 
Ci/well [
 
3
 
H]thymidine for the last 18 h.
Cells were harvested on a cell harvester (Tomtec) and incorpora-
tion of [
 
3
 
H]thymidine was determined using liquid scintillation
counter (model 1205 Betaplate counter; LKB-Wallac).
 
Cytokine Assay.
 
Cloned CD8
 
 
 
 T cells were stimulated with
LCLs prepulsed with Tax11-19 peptide, as described in 
 
Prolifera-
tion Assay
 
. After 48 h of incubation, supernatants were collected
and tested for the presence of cytokines. IFN-
 
 
 
 and IL-4 were
quantified by capture ELISAs as described previously (20). Cyto-
kine contents were calculated from a standard curve. The detec-
tion limits were 100 pg/ml for IFN-
 
 
 
 and 10 pg/ml for IL-4.
 
Immunoprecipitation and Western Blot.
 
TP60 T cells were in-
cubated on ice with LCLs prepulsed with peptides, and warmed
to 37
 
 
 
C for 5 min. The cells were lysed for 15 min on ice by the
addition of cold 2
 
 
 
 lysis buffer (final concentration 1% Nonidet
P-40, 150 mM NaCl, 25 mM Hepes, pH 7.5, 1 mM EDTA, 1
mM sodium orthovanadate, 10 
 
 
 
g/ml leupeptin, and 10 
 
 
 
g/ml
aprotinin). After clarification by centrifugation, detergent ex-
tracts were incubated with agarose-conjugated antiphosphoty-
rosine antibodies (Santa Cruz Biotechnology, Inc.) or anti–TCR
 
 
 
 chain antibody (Santa Cruz Biotechnology, Inc.) plus 25 
 
 
 
l of
protein A/G–agarose, as indicated, for at least 2 h at 4
 
 
 
C. Immu-
noprecipitates were separated by SDS-PAGE on 6–15% acryl-
amide gradient gels and transferred to polyvinylidene difluoride
membranes (Millipore). The membranes were probed with anti-
bodies against phosphotyrosine (a gift from T. Roberts, Dana-
Farber Cancer Institute, Boston, MA), a linker for activation of
T cells (LAT), or PLC-
 
 
 
1 (Santa Cruz Biotechnology, Inc.), fol-
lowed by horseradish peroxidase–coupled secondary Ab (Amer-
sham Biosciences), and developed by ECL™ Western blotting
detection reagents (Amersham Biosciences) according to the
manufacturer’s instructions.
 
Intracellular Staining of pMAPKs and p–c-Jun.
 
LCLs were la-
beled with CFSE and pulsed with peptides as described in 
 
Cyto-
toxicity Assay
 
. T cell clones were cocultured with peptide-pulsed
LCLs for indicated times. The cells were fixed in 4% paraformal-
dehyde for 20 min at room temperature and permeabilized with
permeabilization buffer (PBS containing 0.1% saponin, 0.1% so-
dium azide, and 1% FBS). Phospho–mitogen-activated protein
kinases (MAPKs) and c-Jun were detected by sequentially incu-
bating the cells with mouse anti–phospho-JNK mAb (G-7; Santa
Cruz Biotechnology, Inc.), mouse anti–phospho-p44/42 MAPK
mAb (E10; Cell Signaling Technology), rabbit anti–phospho-p38
Ab (Cell Signaling Technology), or mouse anti–phospho-c-Jun
mAb (KM-1; Santa Cruz Biotechnology, Inc.), followed by bio-
tinylated anti–mouse IgG (Vector Laboratories) or biotinylated
anti–rabbit IgG (Jackson ImmunoResearch Laboratories), and fi-
nally by streptavidin-PE. Each of these incubation steps was for
30 min at room temperature with reagents diluted in permeabili-
zation buffer and was followed by two washes in the same buffer.
The level of phospho-MAPKs and c-Jun in T cells was analyzed
on a flow cytometer (FACScan™; Becton Dickinson) by exclud-
ing CFSE-labeled APCs.
 
Measurement of Calcium Flux.
 
T cell clones were loaded with
2 mg/ml Indo-1, AM (Molecular Probes) ester for 45 min at 37
 
 
 
C
in complete medium. After washing with serum-free media, the
cells were mixed with peptide-pulsed LCLs at a cell ratio of 2:1 in
a serum-free media. After a brief spin, the changes in FL4/FL5 ra-
tio of the cells at 37
 
 
 
C were analyzed for 10 min using FACSVan-
tage™ (Becton Dickinson). The baseline FL4/FL5 ratio was ob-
tained by running Indo-1–labeled T cells alone for 1 min.
 
Results
 
Functional Characteristics of Tax11-19 Reactive CD8
 
 
 
 T
Cell Clones.
 
Using an HLA-A2/Tax11-19 tetramer for
the selection and expansion of antigen-specific CD8
 
 
 
 T
cells, we generated a diverse clonal population of CD8
 
 
 
 T
cells reactive to Tax11-19 from the peripheral blood of an
HLA-A
 
*
 
0201–expressing patient with HTLV-1–associated
myelopathy (17). Five representative T cell clones estab-
lished by this method and one T cell clone established pre-
viously by repeated antigenic stimulation were used in this
work (18). The functional activities of these clones on
the  stimulation with cognate MHC/Ag (HLA-A
 
*
 
0201–
Tax11-19) were examined and summarized in Fig. 1. As
expected, all of the T cell clones exhibited a high degree of
cytotoxic activity accompanied by secretion of 
 
 
 
1 ng/ml
of IFN-
 
 
 
 in an antigen-specific fashion, whereas variable
amounts of proliferation and IL-4 secretion were observed
among different T cell clones (Fig. 1).
 
The Same Antigenic Peptide Presented by APCs with Differ-
ent HLA-A2 Subtypes Behaves Like an Altered Peptide Ligand
(APL).
 
T cells can respond differently to recognition of
variant peptides presented by the same MHC molecule (1,
21–23). As TCRs recognize the bimolecular complex
composed of antigenic peptide and MHC molecule, we
hypothesized that the same antigenic peptide presented on
a variant MHC molecule could induce a partial agonist T
Figure 1. Functional characteristics of Tax11-19–specific T cell clones
on the recognition of cognate MHC/peptide ligand and their TCR V 
chain usage. EBV-transformed B cells expressing HLA-A*0201 incubated
either with or without 50  M Tax11-19 peptide were used as target cells
or APCs. The 51Cr release assay was performed using 10:1 E/T ratio for
the cytotoxic activity. Proliferative activity was assessed by [3H]thymidine
incorporation. IFN-  and IL-4 were measured from culture supernatants
by capture ELISA after 48 h of incubation and the detection limits were
100 and 10 pg/ml for IFN-  and IL-4, respectively. TCR V  chain
usage was determined by indirect immunofluorescence staining using
specific mAb.T
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cell response. To test this possibility, we examined the
functional responses of Tax11-19 reactive CD8
 
 
 
 T cell
clones after antigen stimulation using LCLs expressing dif-
ferent subtypes of HLA-A2 as follows: A
 
*
 
0201, A
 
*
 
0202,
A
 
*
 
0203, A
 
*
 
0205, and A
 
*
 
0206. These HLA-A2 subtypes
have one to four amino acid differences at specific posi-
tions, which are summarized in Table I.
The peptide-antigen dose–response curves measuring
cytotoxic activity of six T cell clones against LCLs express-
 
ing different HLA-A2 subtypes showed a diverse pattern.
As shown in Fig. 2 A, all of the T cell clones elicited a sim-
ilar dose–response cytotoxic activity against LCLs express-
ing HLA-A
 
*
 
0201, with peptide concentrations inducing
half maximal response ranging from 3 nM to 27 nM. LCLs
expressing HLA-A
 
*
 
0206, which differs by only one amino
acid from A
 
*
 
0201, were also lysed in a similar dose–
response manner by all T cell clones, except for TP41 and
KS2E11.7, which needed 10–100 times more peptide for
the same level of cytolysis. Interestingly, the cytolysis pat-
tern of LCLs expressing other HLA-A2 subtypes, which
differ by three or four amino acids, was quite different de-
pending on the individual T cell clones. HLA-A
 
*
 
0202 and
A
 
*
 
0205 loaded with Tax11-19 peptide induced cytotoxic
activity from the TP27 and TP49 T cell clones, but not
from other T cell clones. In contrast, LCLs expressing the
HLA-A
 
*
 
0203 subtype were lysed only by the TP41 and
KS2E11.7 T cell clones, requiring a 10-fold higher dose of
peptide compared with A
 
*
 
0201 (Fig. 2 A). Fig. 2 B sum-
marizes the functional responsiveness including cytotoxic-
ity, proliferation, and IFN-
 
 
 
 secretion of T cell clones
when they were stimulated by peptide complexed with dif-
ferent subtypes of HLA-A2. Overall, A
 
*
 
0203 subtype did
not elicit any functional responsiveness in four T cell
clones, whereas A
 
*
 
0206 induced cytotoxic activities with
or without other functions in all of the T cell clones. Un-
expectedly, the A
 
*
 
0205 subtype induced proliferation with
 
Table I.
 
Summary of Amino Acid Sequences
at Polymorphic HLA-A2 Positions
 
Amino acid sequence at a specific position
 
 
 
1 domain
 
 
 
2 domain
HLA-A2 
subtype 9 43 95 149 152 156
A
 
*
 
0201 F Q V A V L
A
 
*
 
0202 F R L A V W
A
 
*
 
0203 F Q V T E W
A
 
*
 
0205 Y R L A V W
A*0206 Y Q V A V L
Figure 2. Tax11-19–HLA-A*0201 reactive T cell
clones were differentially restricted by HLA-A2 sub-
types. (A) Peptide dose–response cytotoxic activities of
T cell clones. LCLs were pulsed for 2 h at different
peptide concentrations and used as targets in a 51Cr re-
lease assay. The E/T ratio was 10:1 and spontaneous re-
lease of 51Cr was  20%. The lysis of peptide nonpulsed
cells was  5%, and SEM of triplicate wells were  10%.
(B) Summary of CD8  T cell clone functions with
Tax11-19 presentation by different HLA-A2 subtype
molecules. LCLs expressing different HLA-A2 subtypes
were loaded with 50  M Tax11-19 and used as target
cells or APCs. Cytotoxic activity was tested by 51Cr re-
lease assay at an E/T ratio of 10:1. IFN-  was measured
in culture supernatants by ELISA after 48 h of incuba-
tion and the detection limit was 100 pg/ml. Proliferation
was determined by 18 h [3H]thymidine incorporation
assay at the end of a 72-h culture and expressed as S.I.
(stimulation index). N.D., not determined.T
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or without IFN-  secretion in three out of four T cell
clones that did not show cytotoxic activity to this HLA-A2
subtype. Thus, different functional responses of T cell
clones to the same antigenic peptide presented by MHC
class I molecules, which differ at only a few amino acids,
mimic those induced by different antigenic peptides (full
agonist, weak agonist, and partial agonist) presented on the
same MHC class I molecule.
It was possible that these observations could be partially
explained by differences in the binding affinity of the
Tax11-19 peptide to each of the HLA-A2 subtypes. How-
ever, Tax11-19 peptide has similar binding affinity to
HLA-A*0201, A*0202, and A*0205 (24). In addition, the
identical dose–response curves for cytotoxic activity of
TP49 between A*0201 and A*0206, and  1 log difference
between A*0201 and A*0203 for TP41 and KS2E11.7 sug-
gest that Tax11-19 peptide binds well to these HLA-A2
subtypes (Fig. 2 A).
Dissociation of T Cell Function with Stimulation by Tax11-
19–HLA-A*0205. Many papers have demonstrated that
cytotoxic activity can be easily induced in CTLs with weak
stimuli, whereas stronger stimuli are needed to induce pro-
liferation or cytokine secretion of T cells (14, 15, 25).
However, three T cell clones proliferated in response to
Tax11-19 presented by the HLA-A*0205 subtype even
though they did not exhibit any cytotoxic activity (Fig. 2
B). To further explore the selective cytotoxic activity in this
panel of T cell clones, we reevaluated their cytotoxic activ-
ity using increasing E/T ratios and antigen dose. A repre-
sentative noncytotoxic T cell clone (TP60) did not lyse
LCL target cells expressing HLA-A*0205 regardless of in-
creasing E/T ratio or antigen dose, whereas representative
cytotoxic clones (TP49 and TP27) showed typical responses
to increasing E/T ratio and antigen dose (Fig. 3, A and B).
The TP60 T cell clone exhibited a brisk proliferative re-
sponse to Tax11-19 presented by HLA-A*0205 in an anti-
gen dose–dependent manner, in contrast with their total
lack of cytotoxic activity (Fig. 3 B). In these experiments,
cytotoxicity was assessed after a 4-h incubation, whereas
proliferation was measured after a 3-d incubation. Some
peptide ligands have been shown to induce cytotoxicity at
late time points, mainly by a Fas-mediated mechanism with
Figure 3. Tax11-19 presented by HLA-A*0205 did not induce cytotoxic activity from a subset of T cell clones, even at a high E/T ratio, high anti-
genic peptide concentrations, and delayed time points. (A) Specific lysis of 51Cr-labeled LCLs expressing either HLA-A*0201 or A*0205 pulsed with 50
 M Tax11-19 by representative T cell clones was examined at various E/T ratios. (B) Cytotoxic and proliferative activity of T cell clones in response to
various concentration of Tax11-19 presented by HLA-A*0201 (top) or A*0205 (bottom) were determined at a 10:1 E/T ratio by 51Cr release assay and
[3H]thymidine incorporation assay. Cytotoxicity (closed squares) is shown on the left y-axis and proliferation (open circles) on the right y-axis. (C) De-
layed cytotoxicity was examined by counting the viable target cells at late time points as described in Materials and Methods. One representative staining
profile obtained after an 18-h incubation is shown. Results from three independent experiments are summarized in the bottom panel, displaying average
cell number   SD at each time points. There was no statistical significance (P   0.05) in viable target cell numbers between antigen-unpulsed and
Tax11-19–pulsed conditions at any time points, as determined by Student’s t test.T
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an inability to induce early perforin/granzyme-mediated
cytotoxicity (26). LCLs used in our paper express Fas on
their surface (unpublished data). Therefore, we examined
whether HLA-A*0205–presenting Tax11-19 peptide could
induce delayed cytotoxic activity from T cell clones. Due
to the high background in a traditional chromium release
assay at late time points, we used live target cell counts to
measure delayed cytotoxicity (Fig. 3 C). The results ob-
tained using this approach were comparable to results with
the chromium release assay at the 4-h time point when
Tax11-19 presented by HLA-A*0205 did not induce target
cell loss. In contrast, the F3N peptide presented by HLA-
A*0205 induced a 78% decrease in viable target cell num-
ber, which was also detected in chromium release assay (see
Fig. 5). After longer incubation with effector T cells up to
42 h, no statistically significant differences in viable target
cell numbers were detected between antigen-unpulsed and
Tax11-19–pulsed target conditions (Fig. 3 C). In these
analyses, differential target cell division affecting the final vi-
able cell number could be excluded because the CFSE dilu-
tion pattern of target cells was similar between these two
conditions. These data indicate that HLA-A*0205 presenta-
tion of Tax11-19 peptide does not induce cytotoxic activity
from certain T cell clones at either early or late time points
in contrast to its ability to induce late proliferative activity.
One possible explanation for this novel functional dissocia-
tion might be the engagement of inhibitory NK receptors
(27). However, we could not observe any blocking effects
by anti-HLA B, C, or G antibodies, and T cell clones were
not stained with a panel of antikiller inhibitory receptor,
anti-CD94, and anti-CD85 antibodies (unpublished data).
Thus, the engagement of NK receptors was unlikely to be
responsible for this functional dissociation.
Polymorphic Amino Acids at the Peptide-binding Site of
HLA-A2 Molecules Can Affect Functional Responsiveness of T
Cell Clone. The different functional activities of T cells
activated by peptide presentation with different HLA-A2
subtypes may have occurred either from differences on
the MHC residues in direct contact with the TCR or al-
ternatively from the alterations of the peptide structure
buried in the MHC molecule. To address this issue, we
examined which of the polymorphic amino acid residues
associated with allelic variation of HLA-A2 were most
likely to have a direct effect on TCR recognition induc-
ing functional dissociation. This work was based on the
structural data of the trimolecular complex (A6 TCR,
HLA-A*0201, and Tax11-19 peptide) resolved by X-ray
crystallography (6, 28).
As shown in Fig. 4 (a and b), the amino acid residue at
position 9 of HLA-A2 is located in the B-pocket of
groove. However, this position alone is unlikely to affect
the TCR recognition of Tax11-19 because all of the T cell
clones showed similar recognition pattern to both A*0201
and A*0206, which have identical amino acid sequence ex-
cept for this position. The amino acid residue at position 43
of HLA-A2 is located in a loop connecting   sheets, not in
the vicinity of peptide or TCR (Fig. 4, a and b), so this po-
sition is unlikely to have an effect on TCR recognition.
The amino acid residue 95 is situated at the base of the
groove (F-pocket), but is not in direct Van der Waals con-
tact with the peptide (Fig. 4, a and d). A polymorphism at
this position could have an indirect effect on bound pep-
tide structure, although the conservative Val to Leu substi-
tution at this position is unlikely to have a dramatic affect
on the conformation of the bound peptide. Finally, residue
156 is within the Van der Waals radius of the P3 side chain
of the Tax peptide (Fig. 4 c), so the substitution of Leu to a
bulky Trp is more likely to affect the structure of the pep-
tide bound in the MHC molecule and, thus, indirectly af-
fect TCR recognition. This analysis demonstrates that
polymorphic amino acids in the peptide binding site of
HLA-A2 molecule, particularly residue 156, are likely to
affect functional activity of T cell clones.
Single Amino Acid Substitution at the Corresponding Position
of Tax11-19 Can Revert the Altered MHC to Agonistic
MHC. Our analysis suggested that amino acid changes at
the peptide-binding site of the MHC pocket can convert
the agonistic MHC-peptide ligand to partial agonistic
MHC-peptide ligand in some T cell clones. If this is the
case, it should be possible to identify single amino acid
substitutions on the antigenic peptide that bind the rele-
vant HLA-A2 D-pocket and revert the partial agonis-
tic MHC-peptide ligand to an agonistic MHC-peptide
Figure 4. Location of HLA-A2 subtype polymorphic residues. (a and
b) The HLA-A2–Tax11-19 complex viewed from above the peptide
binding groove. The positions of the HLA-A2 subtype polymorphic resi-
dues shown in Table I are marked on the MHC. Residue 9, dark blue;
residue 43, green; residue 95, red; residue 149, cyan; residue 152, yellow;
and residue 156, magenta. The peptide is shown in yellow. (c and d) The
HLA-A2–Tax11-19 complex viewed from within the peptide-binding
groove. The peptide is shown in yellow and the MHC is in blue. (c) The
location of polymorphic residue 156 in the D-pocket. (d) The location of
polymorphic residue 95 in the F-pocket. a, c, and d were drawn using
RIBBONS (44); b was generated with Grasp (45).T
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ligand. This was examined by investigating the responsive-
ness of the T cell clone to the Tax peptide with a single
amino acid substitution at P3 position, which engages the
D-pocket of HLA-A2 molecule. Remarkably, a Phe to
Asn substitution at P3 induced cytotoxic activity against
the A*0205 target cells by TP60 with maintenance of pro-
liferative activity (Fig. 5). TP7 also showed the same but
weak functional restoration of cytotoxicity against A*0205
target cells when Phe was substituted with Met (unpub-
lished data). The requirement for different amino acid sub-
stitutes for the restoration of T cell function may be re-
lated to different TCR structures between these two T cell
clones as revealed by different V  chain usage (Fig. 1) and
different CDR3 region sequences (19). This result dem-
onstrates that depending on individual TCR fine specific-
ity, changing the P3 position of Tax11-19 peptide engag-
ing the D-pocket, which was altered by the Leu to Trp
change, resulted in a gain of function which reverted a
partial agonistic MHC–peptide complex to an agonistic
MHC–peptide complex.
Induction of Weak Early Signaling Events but Sustained c-Jun
Phosphorylation by MHC-altered Peptide Ligand (MAPL).
We further investigated this novel functional dissociation
by analyzing the intracellular signaling pathways activated
upon stimulation. Previous papers indicate that partial ago-
nists can trigger only a subset of early T cell signals (29–31).
Therefore, first we examined phosphorylation status of
TCR-  chain after stimulation with different ligands. TP60
cells incubated with either unpulsed KS.B or DAH cells
showed some level of constitutively phosphorylated TCR- ,
possibly due to the basal activation status of cloned T cells.
There was an increase in TCR-  phosphorylation after
incubation with the agonistic ligands, Tax11-19–HLA-
A*0201 or F3N/HLA-A*0205. However, incubation of
TP60 cells with DAH cells pulsed with Tax11-19 did not
significantly enhance the intensity of TCR-  phosphoryla-
tion (Fig. 6 A). In these experiments, we could not detect
discrete bands of phosphorylated TCR-  chain even with
the strong agonistic stimulation, which has been described
previously in human as well as murine T cells (15, 29). This
difference might come from the use of different antibodies
and/or different experimental approaches.
We further traced downstream signaling pathways.
Consistent with the phosphorylated TCR-  chain profile,
the appearance of the phosphorylated form of ZAP-70
was not detected after stimulation with Tax11-19–HLA-
A*0205 (unpublished data). Phosphorylated LAT was also
barely detectable under this stimulatory condition (Fig. 6
B). Exploring one of the major downstream signaling
pathways after recruitment of the adaptor molecules, LAT
and SLP-76, we found weakly phosphorylated PLC- 1
accompanied by a very weak and transient pattern of Ca2 
flux after stimulation with Tax11-19–HLA-A*0205 (Fig.
6, B and C). As predicted by the functional assays, F3N/
HLA-A*0205 induced activation of TCR- , LAT, and
PLC- 1 albeit to a lesser extent than the strong agonistic
ligand (Tax11-19–HLA-A*0201; Fig. 6, A and B). An-
other ligand, F3R/HLA-A*0201, induces a classical form
of partial agonism, cytotoxicity without proliferation,
from TP60 T cells (Fig. 5). Interestingly, this ligand in-
duced greater activation of all the signaling pathways we
examined as compared to Tax11-19–HLA-A*0205 but
less than F3N/HLA-A*0205 (Fig. 6, A and B, and unpub-
lished data).
Another major signaling pathway in T cell activation is
the Ras–MAPK pathway (32). When we examined phos-
phorylated MAP kinases, including ERK1/2, p38 MAPK,
and JNK, we could not detect the activation of these kinase
pathways after stimulation with Tax11-19–HLA-A*0205
(Fig. 7). However, a high amount of phosphorylated c-Jun
(described previously as one of the signaling intermediates;
reference 33) was detected for a prolonged time period, up
to 42 h after stimulation with Tax11-19–HLA-A*0205
with delayed kinetics even though upstream active kinase,
pJNK, could not be detected at any time points (Fig. 7). In
contrast, a higher amount of p-c-Jun was induced initially
but reverted to background levels within 18 h after stimu-
lation with a classical form of APL, F3R/HLA-A*0201
(Fig. 7). In total, these data demonstrate that Tax11-19–
HLA-A*0205 cannot trigger TP60 TCR strongly enough
to induce early signaling cascades, but can induce the accu-
mulation of signaling intermediates by trickle through the
weak early activation cascade.
Figure 5. Cytotoxic and proliferative responses of TP60 to Tax11-19
peptide analogues with single amino acid substitutions at P3 position pre-
sented by HLA-A*0201 or A*0205. LCLs expressing HLA-A*0201 or
A*0205 were pulsed with 10  M Tax11-19 peptide analogues and were
used as target cells or APCs. Cytotoxicity was measured by a 51Cr release
assay. The E/T ratio was 10:1. Proliferative activity of T cell clones was
measured by [3H]thymidine incorporation assay.T
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Discussion
The same antigenic peptide presented by different MHC
subtypes with subtle differences in MHC sequence induced
partial agonism of T cell function, including an atypical
functional dissociation. This may have occurred either
from differences in the solvent-exposed MHC residues in
direct contact with the TCR or alternatively from the al-
terations of the peptide structure buried in the MHC mol-
ecule. Crystallographic analysis of the peptide binding to
HLA-A2 revealed that whereas the terminal anchor side
chains of antigenic peptides were bound similarly in the
MHC structure, the conformations can be very different in
the center of the binding site. This has led to the conclu-
sion that the peptide itself dominates the antigenic identity
of the MHC–peptide complex through a unique sequence-
dependent conformation that is imposed by the relatively
fixed MHC structure (2). As APLs have been identified as
partial T cell agonists, it might be predicted that subtle vari-
ations of MHC sequence inducing changes in the peptide
conformation available to the TCR, might also induce par-
tial agonism for T cell functions. Examination of the crystal
structure of the trimolecular Tax11-19–HLA-A*0201–A6
TCR complex, in combination with our functional studies,
reveals that changes in predominantly the D- and possibly
F-pockets found with different HLA-A2 subtype are asso-
ciated with partial agonist function of the MHC–peptide
complex. Thus, we demonstrate that MAPLs can induce
partial agonism of T cell function similar to APLs.
It has been shown that each MHC pocket can contribute
to T cell recognition of peptides in an alloresponse (34,
35). Thus, a subpopulation of cytotoxic T cells can recog-
nize all MHC subtypes capable of binding an antigenic
peptide, whereas others are subtype specific. These pub-
lished data are consistent with the differences among T cell
clones in recognizing the Tax11-19 peptide in the context
of different HLA-A2 subtypes we described here. The abil-
ity of MHC class II molecules to change the nature of the
antigenic response has been suggested previously (36). Ger-
main and colleagues demonstrated that a peptide presented
on a mutant MHC class II molecule will induce a response
that is different from the response induced with the native
MHC molecule (36). In this model, the response of a Th1
type murine T cell clone to mutant E E k molecules re-
vealed that peptide inhibited the IL-2 response to an allo-
stimulatory mutant form of the MHC class II molecule.
Although the mutated MHC molecule induced an allore-
active response that was altered by the antigen peptide, it is
not clear if a similar mechanism as observed in the present
paper was operative. Similarly, Doherty et al., also investi-
gating MHC class II restricted responses, demonstrated that
multiple MHC alleles restricted T cell responses in a de-
generative fashion (37). Our investigation demonstrates that
the nature of the functional response to viral peptides is
similarly altered by changes in the peptide-binding pockets
of MHC molecules.
Hierarchies have been observed among partial antigenic
peptide agonists for inducing different T cell functions. Ex-
amination of MHC class I restricted APLs has revealed that
CD8  T cell cytotoxicity has been perhaps the most sensi-
tive indicator of T cell function, with induction of cell cy-
cle and proliferation requiring high strengths of signals (14,
15). Thus, it was surprising that alterations of peptide struc-
Figure 6. Activation of early signaling molecules and Ca2  flux are not
efficiently induced in TP60 T cells by Tax11-19–HLA-A*0205. (A)
Anti–TCR   immunoprecipitates were prepared from lysates made from
107  KS.B (HLA-A*0201) cells alone, 107  DAH (HLA-A*0205) cells
alone, or from 2   107 TP60 cells stimulated for 5 min with KS.B/PBS,
KS.B/F3R, KS.B/Tax11-19, DAH/PBS, DAH/F3N, or DAH/Tax11-19.
Tyrosyl-phosphorylated   chain was detected by immunoblotting with
antiphosphotyrosine antibody and the proteins were visualized by ECL.
(B) Antiphosphotyrosine immunoprecipitates were prepared from lysates
from 107 DAH cells alone, 107 KS.B cells alone, or from 2   107 TP60
cells stimulated for 5 min with DAH/PBS, DAH/Tax11-19, DAH/F3N,
KS.B/PBS, KS.B/Tax11-19, or KS.B/F3R. PLC-  (top) or LAT (bot-
tom) was detected by immunoblotting and the proteins were visualized
by ECL. (C) TP60 T cells were stimulated with 10  M of each peptide
presented by KS.B or DAH and [Ca  ]i increase in T cells was moni-
tored. Arrows indicate the addition of peptide-pulsed APCs. One repre-
sentative experiment of four is shown. N.D., not determined.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
107 Lim et al.
ture imposed by a few amino acid changes in the MHC
could result in the complete loss of cytotoxic function, yet
retain proliferation. These MAPLs also differentially af-
fected cytokine secretion. The loss of cytotoxicity imposed
by A*0205 presentation of Tax11-19 could not be second-
ary to particular characteristics of the APC because single
amino acid mutations of the Tax11-19 peptide at P3,
which is predicted to engage the D-pocket and to induce
conformational changes in the peptide ligand, could restore
cytotoxic function.
Cytotoxicity requires some of the early signaling events
leading to microtubule reorganization for granule exocyto-
sis, whereas proliferation depends on gene expression for
the secretion of growth factors and their receptors (38).
However, the specific intracellular signaling events re-
quired for these functional activities are still poorly under-
stood. Our investigation reveals that MAPL induces
weaker or negligible early signaling events, including
TCR-  chain phosphorylation, LAT phosphorylation, and
calcium flux as compared with the common type of APL
signaling events. In contrast, MAPL provoked sustained
phosphorylation of c-Jun, which was not observed with
APL stimulation. If these signaling events are directly
linked to the functional activity of T cells, it is highly possi-
ble that even though Tax11-19–HLA-A*0205 ligand can-
not trigger TP60 TCRs strongly enough to overcome the
threshold for cytotoxicity, which depends mainly on the
early signaling events such as calcium flux or PKC activity
(39–41), it can engage TCRs for a long enough time to
generate sustained signaling intermediates critical for prolif-
erative activity. This explanation is consistent with revised
kinetic proofreading model for T cell activation recently
proposed by Rosette et al. (33). According to this model,
low-affinity TCR ligands that cannot efficiently induce
early activation events allow late T cell responses by the ac-
cumulated signals that “trickle through” the early activa-
tion cascade.
In summary, we demonstrate that changes in the MHC
pocket associated with alterations of peptide structure
change the hierarchy of T cell effector function. Recipro-
cal amino acid changes in the antigenic peptide engaging
the MHC pocket results in a gain of function mutation.
These data provide evidence for a role of the MHC mole-
cule in providing a scaffolding that subtly changes T cell ef-
fector function depending on the peptide conformation in
the MHC groove. Thus, MHC restriction should not be
regarded as simply a binary event, resulting in a positive or
negative response; instead, subtle variations found among
Figure 7. Phospho-MAPKs are not induced but
phospho-c-Jun is slowly induced and sustained in TP60
T cells after stimulation with Tax11-19–HLA-A*0205.
TP60 T cells were cocultured with LCLs prepulsed
with 10  M of indicated peptides. After incubation for
the indicated times, cells were fixed and intracellularly
stained for phospho-MAPKs and c-Jun. Expression
levels of phospho-MAPKs and c-Jun were analyzed in
T cells with the exclusion of LCLs as described in Ma-
terials and Methods. One representative experiment of
four is shown.T
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MHC alleles can induce a new level of diversity in func-
tional immune responses. What are the potential immuno-
logic consequences of MAPL? It has been shown that co-
presentation of naturally occurring APLs by the same APC
can induce antagonism of T cell function (42, 43). As each
MHC class I molecule has two allelic forms expressed on
the surface, we postulate that in some instances, the same
peptide presented in the context of two different MHC
molecules may be recognized as MAPLs, resulting in either
different functional outcomes or direct antagonism of T
cell function.
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